GlassScriptPhysician profile
John R Hood
NPI 1235126426
$10,818.42
in general payments reported to CMS, 2019-2025
37 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $1,336 · 2021: $1,300 · 2022: $1,253 · 2023: $1,391 · 2024: $1,853 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,633 · Education: $14.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.53 |
| Education | $14.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,121.68 | 2019-2025 | |
| Gilead Sciences, INC. | $1,141.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,132.96 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,049.09 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $834.38 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $563.49 | 2019-2025 | |
| Genzyme Corporation | $245.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.09 | 2022-2025 | Dupixent |
| Celgene Corporation | $214.90 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $203.35 | 2019-2025 | Linzess |
| Qol Medical, LLC | $197.95 | 2019-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $193.20 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $177.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $128.35 | 2019-2025 | |
| Braintree Laboratories, INC. | $120.63 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $120.07 | 2020 | |
| Ferring Pharmaceuticals INC. | $119.92 | 2019-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $93.28 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $88.20 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $87.84 | 2020 | |
| Nestle Healthcare Nutrition INC. | $84.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $73.56 | 2025 | Voquezna |
| Amgen INC. | $72.02 | 2022-2023 | Avsola, Amjevita |
| Celltrion USA INC. | $65.86 | 2023-2025 | Vegzelma, Yuflyma |
| Redhill Biopharma INC. | $63.86 | 2020-2021 | |
| Biocon Biologics INC | $57.65 | 2025 | Yesintek |
| Amag Pharmaceuticals, INC. | $48.24 | 2019-2021 | |
| Lilly USA, LLC | $44.19 | 2025 | Omvoh |
| Orphalan INC | $41.59 | 2025 | Cuvrior |
| Boston Scientific Corporation | $38.62 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Ardelyx, INC. | $36.52 | 2024-2025 | Ibsrela |
| Ucb, INC. | $32.55 | 2019 | |
| Eton Pharmaceuticals, INC. | $24.72 | 2025 | Carglumic Acid, Nitisinone, Betaine Anhydrous |
| Medtronic, INC. | $21.01 | 2025 | Interstim |
| Mallinckrodt Hospital Products INC. | $19.86 | 2020 | |
| Endo Pharmaceuticals INC. | $12.16 | 2019 | |
| Echosens North America, INC. | $10.27 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.